A Phase 3 interventional study of Rivaroxaban and Placebo in Coronavirus Disease 2019 (COVID-19), sponsored by Janssen Research & Development, LLC. Terminated at 17 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-07-18.
Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies testing rivaroxaban in COVID-19 — none open to participants now, none under way, none of them phase 3. Rivaroxaban · COVID-19.
Among the 11 studies testing rivaroxaban in COVID-19, this one is the 2nd largest by enrollment, is one of 11 that started in 2020, is one of 3 in phase 3, and was the 7th registered.
7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.
Browse COVID-19 studies →None of the 11 studies testing rivaroxaban in COVID-19 is open now. The open studies under COVID-19, anywhere →
Rivaroxaban: first FDA approval 2011 (XARELTO), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →
Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 4 · Phase 3 4 · Phase 4 3
First in 2020; this study’s year is marked. 11 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,284 is above the median of 102 across 4,367 interventional studies indexed under COVID-19.
Median enrollment 497 across the 11 interventional studies. Of the 9 that completed or were terminated, 2 (22%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 11 have an industry lead sponsor. The 10 most frequent:
This study is registered under Janssen Research & Development, LLC, one of the names counted as Johnson & Johnson. Under that name alone:
Janssen Research & Development, LLC is the lead sponsor of 932 studies on the registry; 76 are open to participants now.
Of its 285 completed or terminated interventional studies of FDA-regulated products, 137 (48%) have results posted.
10 studies in COVID-19 by Johnson & Johnson: none open now, none under way, none of them phase 3. Of 10 finished, 9 (90%) have results posted.
Among the 10 studies in COVID-19 by Johnson & Johnson, this one is the 4th largest by enrollment, is one of 5 that started in 2020, is one of 5 in phase 3, and was the 4th registered.
Johnson & Johnson’s COVID-19 studies by the year they started, since 2020.
None of the studies under way reaches primary completion within a year.
Among the 11 studies testing rivaroxaban in COVID-19, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Johnson & Johnson’s 10 in COVID-19:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate whether rivaroxaban reduces the risk of a composite endpoint of major venous and arterial thrombotic events, all-cause hospitalization, and all-cause mortality compared with placebo in outpatients with acute, symptomatic Coronavirus Disease 2019 (COVID-19) Infection.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive rivaroxaban 10 milligram (mg) tablet orally once daily for 35 Days along with standard of care treatment (SOC).
Drug: Rivaroxaban · Other: Standard of Care (SOC)
Participants will receive matching placebo tablet orally once daily for 35 Days along with SOC.
Other: Placebo · Other: Standard of Care (SOC)
Participants will receive rivaroxaban 10 mg tablet orally once daily.
Also known as: JNJ-39039039, BAY 59-7939
Participants will receive matching placebo tablet orally once daily.
SOC treatment will be determined by the investigator based on local practice and consists of supportive care.
Number of Participants With Time to First Occurrence of Primary Efficacy Composite Endpoint
Number of participants with time to first occurrence of primary efficacy composite endpoint were reported. Time to first occurrence of primary efficacy composite endpoint is defined as time from randomization to first occurrence of any component of the primary endpoint. The components were: symptomatic venous thromboembolism (VTE), myocardial infarction (MI), ischemic stroke, acute limb ischemia, non-central nervous system (non-CNS) systemic embolization, all-cause hospitalization, and all-cause mortality.
Time frame: Up to Day 35
Number of Participants With Time to First Occurrence of The Principle Safety Outcome (Fatal Bleeding and Critical Site Bleeding) Based on a Modification of the International Society on Thrombosis and Haemostasis (ISTH) Criteria
Number of participants with time to first occurrence of the principle safety outcome (fatal bleeding and critical site bleeding) based on a Modification of the ISTH criteria were reported. Fatal bleeding is defined as any bleeding event that leads to fatal outcome. Critical site bleeding defined as any bleeding event that occurred at critical site such as intracranial, intra-spinal, intraocular, pericardial, intra-articular, intra-muscular with compartment syndrome, retroperitoneal.
Time frame: Up to Day 35
Number of Participants With Time to the First Occurrence of Secondary Efficacy Outcomes
Number of participants with time to the first occurrence of secondary efficacy outcomes which included thrombotic events (symptomatic VTE, myocardial infarction, ischemic stroke, acute limb ischemia, non-CNS systemic embolization), emergency room (ER) visit, all-cause mortality, all-cause hospitalization, any thrombotic outcome and all-cause mortality, and any thrombotic outcome and all-cause hospitalization, were reported.
Time frame: From Day 1 up to Day 35
Number of Participants With Time to First Occurrence of Major Bleeding Based on a Modification of the ISTH Criteria
Number of participants with time to first occurrence of the major bleeding based on a modification of the ISTH criteria were reported. Major bleeding is defined as clinically overt bleeding that is associated with a reduction in hemoglobin of 2 grams per deciliter (g/dL) or more, or a transfusion of 2 or more units of packed red blood cells or whole blood, or occurrence at a critical site defined as intracranial, intra-spinal, intraocular, pericardial, intra-articular, intra-muscular with compartment syndrome, retroperitoneal, or fatal outcome.
Time frame: Up to Day 35
Number of Participants Who Were Hospitalized or Dead on Day 35
Number of participants who were hospitalized or dead on Day 35 were reported.
Time frame: At Day 35 (+/- 6 days)
| Milestone | Rivaroxaban 10 Milligrams (mg) | Placebo |
|---|---|---|
| Started | 641 | 643 |
| Treated (safety analysis set) | 599 | 598 |
| Completed | 640 | 641 |
| Not completed | 1 | 2 |
| Withdrew: Withdrawal by subject | 1 | 2 |
Number of participants with time to first occurrence of primary efficacy composite endpoint were reported. Time to first occurrence of primary efficacy composite endpoint is defined as time from randomization to first occurrence of any component of the primary endpoint. The components were: symptomatic venous thromboembolism (VTE), myocardial infarction (MI), ischemic stroke, acute limb ischemia, non-central nervous system (non-CNS) systemic embolization, all-cause hospitalization, and all-cause mortality.
| Participants | Rivaroxaban 10 Milligrams (mg) | Placebo |
|---|---|---|
| Number of Participants With Time to First Occurrence of Primary Efficacy Composite Endpoint | 22 | 19 |
Number of participants with time to first occurrence of the principle safety outcome (fatal bleeding and critical site bleeding) based on a Modification of the ISTH criteria were reported. Fatal bleeding is defined as any bleeding event that leads to fatal outcome. Critical site bleeding defined as any bleeding event that occurred at critical site such as intracranial, intra-spinal, intraocular, pericardial, intra-articular, intra-muscular with compartment syndrome, retroperitoneal.
| Participants | Rivaroxaban 10 Milligrams (mg) | Placebo |
|---|---|---|
| Fatal Bleeding | 0 | 0 |
| Critical Site Bleeding | 0 | 0 |
Number of participants with time to the first occurrence of secondary efficacy outcomes which included thrombotic events (symptomatic VTE, myocardial infarction, ischemic stroke, acute limb ischemia, non-CNS systemic embolization), emergency room (ER) visit, all-cause mortality, all-cause hospitalization, any thrombotic outcome and all-cause mortality, and any thrombotic outcome and all-cause hospitalization, were reported.
| Participants | Rivaroxaban 10 Milligrams (mg) | Placebo |
|---|---|---|
| Symptomatic VTE | 0 | 3 |
| Myocardial Infraction | 0 | 0 |
| Ischemic stroke | 0 | 2 |
| Acute limb ischemia | 0 | 0 |
| Non-CNS systemic embolization | 0 | 0 |
| ER Visit | 26 | 34 |
| All-cause hospitalization | 21 | 17 |
| All-cause Mortality | 2 | 2 |
| Any Thrombotic Outcome and All-cause Mortality | 2 | 7 |
| Any Thrombotic Outcome and All-cause Hospitalization | 21 | 17 |
Number of participants with time to first occurrence of the major bleeding based on a modification of the ISTH criteria were reported. Major bleeding is defined as clinically overt bleeding that is associated with a reduction in hemoglobin of 2 grams per deciliter (g/dL) or more, or a transfusion of 2 or more units of packed red blood cells or whole blood, or occurrence at a critical site defined as intracranial, intra-spinal, intraocular, pericardial, intra-articular, intra-muscular with compartment syndrome, retroperitoneal, or fatal outcome.
| Participants | Rivaroxaban 10 Milligrams (mg) | Placebo |
|---|---|---|
| Number of Participants With Time to First Occurrence of Major Bleeding Based on a Modification of the ISTH Criteria | 1 | 0 |
Number of participants who were hospitalized or dead on Day 35 were reported.
| Participants | Rivaroxaban 10 Milligrams (mg) | Placebo |
|---|---|---|
| Number of Participants Who Were Hospitalized or Dead on Day 35 | 5 | 3 |
Collected over Adverse Event collection started from screening up to Day 49 post-treatment follow-up. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Rivaroxaban 10 Milligrams (mg) | 2/641 (0.3%) | 1/599 (0.2%) | 57/599 (9.5%) |
| Placebo | 2/643 (0.3%) | 0/598 (0%) | 50/598 (8.4%) |
| Event | Rivaroxaban 10 Milligrams (mg) | Placebo |
|---|---|---|
| Drug HypersensitivityImmune system disorders | 1/599 | 0/598 |
| Event | Rivaroxaban 10 Milligrams (mg) | Placebo |
|---|---|---|
| HeadacheNervous system disorders | 5/599 | 7/598 |
| ContusionInjury, poisoning and procedural complications | 3/599 | 6/598 |
| NauseaGastrointestinal disorders | 2/599 | 5/598 |
| Abdominal Pain UpperGastrointestinal disorders | 5/599 | 1/598 |
| DiarrhoeaGastrointestinal disorders | 4/599 | 1/598 |
| Dry MouthGastrointestinal disorders | 4/599 | 0/598 |
| Muscle SpasmsMusculoskeletal and connective tissue disorders | 4/599 | 3/598 |
| DizzinessNervous system disorders | 4/599 | 2/598 |
| Covid-19Infections and infestations | 3/599 | 2/598 |
| RashSkin and subcutaneous tissue disorders | 3/599 | 2/598 |
| Age, Continuous(years) | Rivaroxaban 10 Milligrams (mg) | Placebo | Total |
|---|---|---|---|
| Mean | 56.3 ± 13.07 | 55.7 ± 13.3 | 56 ± 13.18 |
| Sex: Female, Male(Participants) | Rivaroxaban 10 Milligrams (mg) | Placebo | Total |
|---|---|---|---|
| Female | 399 | 384 | 783 |
| Male | 242 | 259 | 501 |
| Ethnicity (NIH/OMB)(Participants) | Rivaroxaban 10 Milligrams (mg) | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 95 | 97 | 192 |
| Not Hispanic or Latino | 520 | 508 | 1028 |
| Unknown or Not Reported | 26 | 38 | 64 |
| Race (NIH/OMB)(Participants) | Rivaroxaban 10 Milligrams (mg) | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 1 | 5 | 6 |
| Asian | 25 | 16 | 41 |
| Native Hawaiian or Other Pacific Islander | 3 | 2 | 5 |
| Black or African American | 61 | 65 | 126 |
| White | 465 | 464 | 929 |
| More than one race | 1 | 1 | 2 |
| Unknown or Not Reported | 85 | 90 | 175 |
| Region of Enrollment(Participants) | Rivaroxaban 10 Milligrams (mg) | Placebo | Total |
|---|---|---|---|
| United States | 641 | 643 | 1284 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — The data sharing policy of the Janssen Pharmaceutical Companies of Johnson \& Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
Data sharing details ↗ · www.janssen.com
Ran from Aug 2020 to primary completion in Jun 2022, 21 months.
Results were first posted in Jul 2023, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Rivaroxaban
Janssen Research & Development, LLC →